MK-8237 12 DU

BIOLOGICAL2 trials

Sponsors

ALK-Abelló A/S

Conditions

Rhinitis, Allergic, NonseasonalRhinitis, Allergic, Perennial

Phase 1

Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)

CompletedNCT01678807

ALK-Abelló A/SRhinitis, Allergic, Nonseasonal, Rhinitis, Allergic, Perennial

Start: 2012-10-31End: 2013-05-31Updated: 2017-09-15

Phase 2

A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)

CompletedNCT01644617

ALK-Abelló A/SRhinitis, Allergic, Nonseasonal, Rhinitis, Allergic, Perennial

Start: 2012-10-31End: 2013-08-31Updated: 2017-09-15

Related Papers

Clinical efficacy of sublingual immunotherapy is associated with restoration of steady-state serum lipocalin 2 after SLIT: a pilot study.

2018-10-0115 citations

Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial.

2016-12-0124 citations

Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.

2015-11-0629 citations